Please login to the form below

Not currently logged in
Email:
Password:

RNA

This page shows the latest RNA news and features for those working in and with pharma, biotech and healthcare.

Redmile and Google help Evox raise £35.5m for exosome pipeline

Redmile and Google help Evox raise £35.5m for exosome pipeline

Boehringer Ingelheim on an undisclosed RNA target and another, unnamed partner on using exosomes to deliver small-molecules for a CNS disease.

Latest news

More from news
Approximately 4 fully matching, plus 106 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    32.5. Ethris (DE). AstraZeneca (GB). R&D collaboration option to license. Stabilised non-immunogenic modified RNA technology for respiratory diseases.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    But ultimately deals will continue in a diverse range of therapeutic entities as technological improvements appear to be bearing fruit in areas such as gene therapy and RNA-based therapeutics.

  • Deal Watch December 2016 Deal Watch December 2016

    Arcturus. Takeda. Not disclosed. Not disclosed. RNA-based therapeutics using oligomer technology.

  • Deal Watch June 2016 Deal Watch June 2016

    Cerus' Intercept technology is based on amotosalen (a well characterised photoactive compound that specifically targets DNA and RNA) and UVA illumination to irreversibly cross-link nucleic acids thereby blocking the replication

  • Pharma deals in August 2015 Pharma deals in August 2015

    $65m. Antisense oligonucleotides target RNA and the new collaboration will extend into renal diseases, cardiovascular and metabolic fields.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. ... As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors.

  • MIT chief financial officer joins Moderna Therapeutics MIT chief financial officer joins Moderna Therapeutics

    We look forward to leveraging Israel's insights as Moderna evolves into a leading, clinical stage biotechnology company by harnessing the promise of messenger RNA science to improve lives.”.

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics